AstraZeneca plc (AZN) Given a GBX 6,000 Price Target at Citigroup Inc.

Citigroup Inc. set a GBX 6,000 ($77.49) price target on AstraZeneca plc (LON:AZN) in a research report released on Wednesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on AZN. UBS AG set a GBX 5,150 ($66.51) price target on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Tuesday, June 27th. Shore Capital restated a hold rating on shares of AstraZeneca plc in a research note on Monday, September 11th. J P Morgan Chase & Co set a GBX 4,200 ($54.24) price target on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Wednesday, August 9th. Jefferies Group LLC upped their price target on shares of AstraZeneca plc from GBX 4,350 ($56.18) to GBX 4,800 ($61.99) and gave the company a hold rating in a research note on Monday, September 11th. Finally, Bryan, Garnier & Co upgraded shares of AstraZeneca plc to a buy rating and upped their price target for the company from GBX 4,700 ($60.70) to GBX 5,380 ($69.48) in a research note on Monday, September 11th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of GBX 5,022.91 ($64.87).

AstraZeneca plc (LON:AZN) opened at 4719.50 on Wednesday. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The company’s market capitalization is GBX 59.75 billion. The stock’s 50 day moving average is GBX 4,556.15 and its 200-day moving average is GBX 4,880.61.

COPYRIGHT VIOLATION WARNING: This article was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://transcriptdaily.com/2017/09/17/astrazeneca-plc-azn-given-a-gbx-6000-price-target-at-citigroup-inc.html.

The company also recently announced a dividend, which was paid on Monday, September 11th. Shareholders of record on Thursday, August 10th were given a dividend of GBX 68.90 ($0.89) per share. This represents a yield of 1.35%. The ex-dividend date was Thursday, August 10th.

In other news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply